Q&A Genmab 2020-08-26

	26/8 16:56 af Jan Van de Winkel	The Zymeworks bispecifics have numerous unnatural mutations and are thus less likely to function as regular IgGs.
	26/8 16:57 af Sukkeralf	Have Genmab looked more into the liver toxicity in the DR5/DR5 HexaBody study - has it have something to do with the epitopes you hit or maybe the kinetics around the suicide signal or........??
	26/8 16:58 af Jan Van de Winkel	At present Genmab is very actively exploring safety and efficacy of HexaBody DR5/DR5 and expects to have the data to base decisions for next steps within 2020..
	26/8 16:58 af Jan Van de Winkel	We also have the DuoHexaBody-CD37 program in active clinical development which is progressing well..
	26/8 16:59 af Jan Van de Winkel	And are most excited and enthusiastic HexaBody-CD38 that is prepared for clinical production in the coming months as well.
	26/8 16:59 af Solsen	Mr Winkel We look forward to se data on the PD-L1 x 4-1BB. When could that be and what year could the antibody be on the market ?
	26/8 17:00 af Jan Van de Winkel	We expect the first clinical data to be presented in November at a key medical conference, and cannot wait for that exciting moment.
	26/8 17:01 af Akshay1976	APOLLO is like a confirmatory trial of EQUULEUS trial (3L+ MM)..but APOLLO trial also includes 2L+ MM patients..will FDA/EMA approve for 2L+ or 3L+?
	26/8 17:02 af Jan Van de Winkel	The regulatory decision is up to the regulators, we are very pleased with the data that are also expected to be presented at a key medical conference in the coming months.
	26/8 17:03 af acampi	Congratulations on the exciting partnership with Abbvie! Are there any compounds in the Abbvie portfolio that you are interested in combining with epcoritamab?
	26/8 17:04 af Jan Van de Winkel	Thank you for the congratulations, and yes, there are several compounds that we would like to combine with epcoritamab. More information on the expansive development program for epco will become available in the coming months..
	26/8 17:04 af Jan Van de Winkel	Exciting times.
	26/8 17:05 af acampi	When can we expect initiation of the next phase of epcoritamab trials?
	26/8 17:05 af Jan Van de Winkel	We are expanding the development program for epcoritamab very actively.
	26/8 17:06 af Sukkeralf	You have a clear strategy of focusing on the winners (like epcoritamab and PD-L1/4-1BB) - when and how will you cut down the "loosers"?
	26/8 17:07 af Jan Van de Winkel	Genmab is a data driven company and expects to take decisions on next steps once the key data are available for the different programs..
	26/8 17:07 af Jan Van de Winkel	We intend to keep focus on the potential winners and base our decisions on next steps in development on hard facts.
	26/8 17:08 af Solsen	Mr Winkel What is the updated timeline for Camidanlumab and have you seen data now ?
	26/8 17:08 af Jan Van de Winkel	This is a question for ADC-Therapeutics.
	26/8 17:09 af Bulder	Now that you can expect a solid royalty stream from Darzalex, Tepezza and Kesimpta and the fact that you have a cash position of more than DKK 12 bn, it seems that you have more than enough money for future development. Would a share buy back programme be an option?
	26/8 17:10 af Jan Van de Winkel	Genmab is very focused on creating differentiated antibody therapeutics for cancer and intends to increasingly hold on to ownership of its therapeutics..
	26/8 17:11 af Jan Van de Winkel	This requires us to continue to invest i further strengthening and broadening our product pipeline.
	26/8 17:11 af Helge Larsen/PI-redaktør	And now to the last question.
	26/8 17:11 af Rahul Trivedi	Also, what would be the hospitalization period for teclistamab? I believe this would play a key factor when competing with the BCMA CAR-Ts given the frequent bispecific dosing

	26/8 17:12 af Jan Van de Winkel	This is a question for Janssen who is developing Teclistamab.
	26/8 17:12 af Helge Larsen/PI-redaktør	Thank You for joining us and thank you for the many fullfilling answers to our questions. We look forward to seeing you back here on ProInvestor.com after Q3.
	26/8 17:13 af Jan Van de Winkel	Thank you for a lively and energizing session. Looking forward to chat soon.
	26/8 17:13 af Helge Larsen/PI-redaktør	This session have ended.